Drug Prior Authorization Form
Praluent (alirocumab), Repatha (evolocumab)

The purpose of this form is to obtain information required to assess your drug claim.

IMPORTANT: Please answer all questions. Your claim assessment will be delayed if this form is incomplete or contains errors.

Any costs incurred for the completion of this form are the responsibility of the plan member/patient.

Canada Life recognizes and respects the importance of privacy. Personal information collected is used for the purposes of assessing eligibility for this drug and for administering the group benefits plan. For a copy of our Privacy Guidelines, or if you have questions about Canada Life's personal information policies and practices (including with respect to service providers), refer to www.canadalife.com or write to Canada Life's Chief Compliance Officer.

I authorize Canada Life, any healthcare provider, my plan administrator, any insurance or reinsurance company, administrators of government benefits or patient assistance programs or other benefits programs, other organizations, or service providers working with Canada Life or any of the above, located inside or outside Canada, to exchange personal information when relevant and necessary for these purposes. I understand that personal information may be subject to disclosure to those authorized under applicable law within or outside Canada.

I acknowledge that the personal information is needed to assess eligibility for this drug and to administer the group benefits plan. I acknowledge that providing consent will help Canada Life to assess my claim and that refusing to consent may result in delay or denial of my claim. Canada Life reserves the right to audit the information provided on this form at any time and this consent extends to any audit of my claim. This consent may be revoked by me at any time by sending written instruction to that effect.

I also consent to the use of my personal information for Canada Life and its affiliates' internal data management and analytics purposes.

If the patient is a person other than myself, I confirm that the patient has given their consent to provide their personal information and for Canada Life to use and disclose it as set out above.

I certify that the information given below is true, correct, and complete to the best of my knowledge. Failure to provide true, correct and complete information on this form could result in revocation of any approval decision, a requirement to repay paid claims or other appropriate action.

Plan Member's signature: _____ Date: _____

Form Completion Instructions:

1. **Complete "Patient Information" sections.**
2. **Have the prescribing physician complete the "Physician Information" sections.**
3. **Send all pages of the completed form to us by mail, fax or email as noted below.**

Note: As email is not a secure medium, any person with concerns about their prior authorization form/medical information being intercepted by an unauthorized party is encouraged to submit their form by other means.

Mail to: **The Canada Life Assurance Company**
Drug Claims Management
PO Box 6000
Winnipeg MB R3C 3A5

Fax to: **The Canada Life Assurance Company**
Fax 1-204-946-7664
Attention: Drug Claims Management

Email to: **cldrug.services@canadalife.com**
Attention: Drug Claims Management

For additional information regarding Prior Authorization and Health Case Management, please visit our Canada Life website at www.canadalife.com or contact Group Customer Contact Services at 1-800-957-9777. Deaf or hard of hearing and require access to a telecommunications relay service? Please contact us at 711 for TTY to Voice or 1-800-855-0511 for Voice to TTY.

(Continued on next page)

M6453(REPAPRAL)-8/20

canada life™

Patient Information
Praluent (alirocumab), Repatha (evolocumab)

Plan Member Information – Complete all sections of this page (please print)

Plan Member:	Patient Name:	
Plan Name:	Plan Number:	Plan Member ID Number:
Patient Date of Birth (DD/MM/YYYY):	Address (number, street, city, province, postal code):	

Please indicate preferred contact number and if there are any times when telephone contact with you about your claim would be most convenient.

May we contact you by email? (Note that some correspondence may still need to be sent by regular mail).

☐ Yes ☐ No If yes, please provide email address: _____

Tell us if you have been on this drug before

Is the patient currently on, or previously been on this drug? ☐ Yes ☐ No

If Yes, a) indicate start date (DD/MM/YYYY): _____

b) coverage provided by: _____

(if coverage is not provided by Canada Life please provide pharmacy print-out showing purchase of this drug)

Tell us if you have coverage with any other benefits plan

Does the patient have drug coverage under any other group benefits plan? ☐ Yes ☐ No

If Yes, name of other Insurance Company: _____

If other plan is with Canada Life, tell us the plan and ID number: _____

Name of plan member: _____

Relationship to patient: _____

Provide details and attach documentation of acceptance or decline:

_____

_____

Tell us about any Provincial or other coverage you may have

Does the patient have coverage under a provincial program or from any other source? ☐ Yes ☐ No

If Yes, name of program or other source: _____

Provide details and attach documentation of acceptance or decline: _____

Is the patient currently receiving disability benefits for the condition for which this drug has been prescribed? ☐ Yes ☐ No

Tell us about any Patient Assistance Program you might be enrolled in

Has the patient enrolled in the patient assistance program for this drug? ☐ Yes ☐ No

If Yes, please provide the following information:

1. Patient assistance program patient ID Number: _____
2. Patient assistance program contact person name and phone number:

   Contact Name: _____ Phone Number: _____

(Continued on next page)

Physician Information
Praluent (alirocumab), Repatha (evolocumab)

Note to Physician: In order to assess a patient's claim for this drug, we require detailed information on the patient's prescription drug history as requested below.

Attach extra information if necessary. *GENETIC TEST RESULTS ARE NOT REQUIRED*

Physician's Information (please print)

Name of prescribing physician:

Specialty:

Address (number, street, city, province, postal code):

Telephone Number (including area code):	Fax Number (including area code):

1. Prescribed Medication:
   - ☐ Praluent (alirocumab)
   - ☐ Repatha (evolocumab)
2. Health Canada indication (include date of initial diagnosis) (MM/YYYY): _____

[1]Approved Health Canada Indications and Clinical Use for Praluent:

☐ Prevention of Cardiovascular Events

[1]Praluent (alirocumab injection) is indicated in combination with a maximum tolerated dose of a statin, with or without other lipid lowering therapies, to reduce the risk of myocardial infarction, ischemic stroke, and unstable angina requiring hospitalization in adults with established cardiovascular disease.

☐ Primary Hyperlipidemia

[1]Praluent (alirocumab injection) is indicated for the reduction of low density lipoprotein cholesterol (LDL-C) in adults with primary hyperlipidemia (heterozygous familial and non-familial):

- As an adjunct to diet and statin therapy, with or without other lipid-lowering therapies;
- As an adjunct to diet, as monotherapy or in combination with other non-statin lipid-modifying therapies, in patients for whom a statin is contraindicated

[2]Approved Health Canada Indications and Clinical Use for Repatha:

☐ Prevention of Cardiovascular Events

[2]Repatha is indicated as an adjunct to diet and standard of care therapy (including moderate- to high-intensity statin therapy alone or in combination with other lipid-lowering therapy), to reduce the risk of myocardial infarction, stroke, and coronary revascularization in adult patients with atherosclerotic cardiovascular disease

☐ Primary Hyperlipidemia (including Heterozygous Familial Hypercholesterolemia)

[2]Repatha is indicated for the reduction of elevated low density lipoprotein cholesterol (LDL-C) in adult patients with primary hyperlipidemia (including heterozygous familial hypercholesterolemia):

- as an adjunct to diet and statin therapy, with or without other lipid-lowering therapies, in patients who require additional lowering of LDL-C
- as an adjunct to diet, alone or in combination with non-statin lipid-lowering therapies, in patients for whom a statin is contraindicated

☐ Homozygous Familial Hypercholesterolemia

[2]Repatha is indicated as an adjunct to diet and other LDL-lowering therapies (e.g., statins, ezetimibe, LDL apheresis) in adult patients and adolescent patients aged 12 years and over with homozygous familial hypercholesterolemia (HoFH) who require additional lowering of LDL-C.

☐ Other (approved by Health Canada): _____

Complete questions 1 - 7 and Other condition (Health Canada approved)

(Continued on next page)

canada life™

Physician Information
Praluent (alirocumab), Repatha (evolocumab)

Physician's Information *(continued)* (please print)

Is this drug being prescribed in accordance with approved Health Canada indications[1,2]?

☐ Yes, complete questions 1 – 7 and Physician's Information

☐ No, prescribed use is not approved by Health Canada: _____

Complete questions 1 – 7 and Off-label use

Prescribed dosage and regimen: _____

Provide rationale _____

3. What is the anticipated duration of treatment with this drug? _____
4. Where will treatment be administered? ☐ Home ☐ Physician's Office ☐ Private clinic ☐ Hospital in-patient ☐ Hospital out-patient
5. Please provide medical rationale why this drug has been prescribed instead of an alternate drug in the same therapeutic class.

_____

_____

6. Drug and Treatment History – **must be completed for every request.**

NON-STATIN Drug History

Drug(s) and Treatment(s) past and present	Dosing Regimen	Start Date (DD/MM/YYYY)	End Date (DD/MM/YYYY)	Clinical Results/Outcome
				☐ Failure ☐ Intolerance ☐ Other Clinical details:
				☐ Failure ☐ Intolerance ☐ Other Clinical details:

STATIN Drug History

Name of Statin	Dosing Regimen	Start Date (DD/MM/YYYY)	End Date (DD/MM/YYYY) Or Currently On	Patient responses: Reason for discontinuation, Details of intolerance, or failure at maximum tolerated dose must be provided
				☐ Persistent myopathy or myalgia for at least 2 weeks ☐ Myositis or Rhabdomyolysis ☐ Other - please detail:
				☐ Persistent myopathy or myalgia for at least 2 weeks ☐ Myositis or Rhabdomyolysis ☐ Other - please detail:
				☐ Persistent myopathy or myalgia for at least 2 weeks ☐ Myositis or Rhabdomyolysis ☐ Other - please detail:

(Continued on next page)

canada life™

Physician Information
Praluent (alirocumab), Repatha (evolocumab)

Physician's Information *(continued)* (please print)

7. STATIN history questions

a. Is the patient currently taking a maximally-tolerated dose of statin therapy for at least 4 weeks and is expected to continue on statin therapy? ☐ Yes ☐ No

b. Does patient have any contraindications to statin use, such as pregnancy, breast feeding, active liver disease or unexplained persistent elevations of serum transaminases exceeding 3x upper limit of normal?

☐ Yes – please list contraindication: _____

☐ No

c. Is patient considered intolerant to statins?

☐ Yes – please ensure details of intolerance to at least 2 different statins is documented in the STATIN history chart on the previous page

☐ No

Prevention of Cardiovascular Events – Genetic test results are not required

Patient's ASCVD history:

☐ Acute coronary syndromes
☐ History of myocardial infarction (MI)
☐ Stable or unstable angina
☐ Coronary or other arterial revascularization
☐ Stroke
☐ Transient ischemic attack (TIA)
☐ Peripheral arterial disease presumed to be of atherosclerotic origin

Please submit the listed reports to assist with the review:
- Patient's most recent LDL-C lab result (must be current within 6 months of application)

Will the patient be following a low cholesterol diet while taking Praluent/Repatha? ☐ Yes ☐ No

Primary Hyperlipidemia - Genetic test results are not required

Has patient been diagnosed with heterozygous familial hypercholesterolemia or another form of primary hyperlipidemia? ☐ Yes ☐ No

Please submit the listed reports to assist with the review:
- Most recent LDL test result (must be current within 6 months of application)
- **Laboratory results and clinic notes that support the diagnosis and describe the patient's clinical manifestations of disease**

Will the patient be following a low cholesterol diet while taking Praluent/Repatha? ☐ Yes ☐ No

(Continued on next page)

Physician Information
Praluent (alirocumab), Repatha (evolocumab)

Physician's Information *(continued)* (please print)

Homozygous Familial Hypercholesterolemia (HoFH) – Repatha only – Genetic test results are not required

Has the diagnosis been confirmed by any of the following? (check all that apply)

- ☐ History of untreated elevated LDL-C concentration > 13 mmol/L
- ☐ Xanthoma before 10 years of age.
- ☐ Evidence of heterozygous familial hypercholesterolemia in both parents

Please submit the listed reports to assist with the review:
- Patient's most recent LDL-C level (must be current within 6 months of request date)
- Untreated elevated LDL-C concentration >13 mmol/L

Will the patient be following a low cholesterol diet while taking Repatha? ☐ Yes ☐ No

Other condition (Health Canada approved) – Genetic test results are not required

Please provide any relevant information related to the disease and attach supporting documentation.

Off-label use – Genetic test results are not required

Questions 1-7 must be completed.

Is there clinical evidence supporting the off-label use of this drug? ☐ Yes ☐ No

Provide clinical literature/studies to support the request for off-label use, such as:

- At least two Phase II or two Phase III clinical trials showing consistent results of efficacy; and
- Published recommendations in evidence-based guidelines supporting its use.

Provide medical rationale why this drug has been prescribed off-label instead of an alternate drug with an approved indication for this condition.

Provide any pertinent medical history or information to support this off-label request.

If this is a renewal request, provide documentation showing treatment efficacy since previous request.

Physician Information
Praluent (alirocumab), Repatha (evolocumab)

Note for Physician: To be eligible for reimbursement, Canada Life may require your patient to purchase a drug requiring prior authorization from a pharmacy designated by Canada Life. If applicable, a health case manager will contact you with further information.

I certify that the information provided is true, correct, and complete.

Physician's Signature: _____ Date: _____

License Number: _____

It is important to provide the requested information in detail to help avoid delay in assessing claims for the above drug. This form may be subject to audit. The completed form can be returned to Canada Life by mail, fax, or email.

Note: As email is not a secure medium, any person with concerns about their prior authorization form/medical information being intercepted by an unauthorized party is encouraged to submit their form by other means.

Mail to: **The Canada Life Assurance Company**
Drug Claims Management
PO Box 6000
Winnipeg MB R3C 3A5

Email to: **cldrug.services@canadalife.com**
Attention: Drug Claims Management

Fax to: **The Canada Life Assurance Company**
Fax 1-204-946-7664
Attention: Drug Claims Management